文献速递冠心病血脂与心血管预防

降低脂蛋白(a)以减少冠心病结局所需效应量的孟德尔随机化分析

Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis.
PubMed 文献 · JAMA Cardiol · 2019-01-01

该遗传流行病学研究采用孟德尔随机化分析,利用5项以人群为基础的欧洲血统研究的Lp(a)遗传效应估计及CHD Exome+联盟的冠心病风险数据,估算降低Lp(a)所需效应量。结果显示,要达到降低LDL-C 38.67 mg/dL对临床结局的同等潜在效果,需降低Lp(a) 65.7 mg/dL(95%CI 46.3-88.3)。该估计受Lp(a)检测标准化影响,既往对药物所需Lp(a)降低潜力的计算可能被高估。

要点

  • 要达到降低LDL-C 38.67 mg/dL的同等冠心病结局效果,需降低Lp(a) 65.7 mg/dL。
  • 该估计基于27个SNP对Lp(a)浓度的效应及对冠心病风险的效应。
  • Lp(a)检测标准化影响效应量估计,既往所需降低幅度可能被高估。

核心结论

  • 孟德尔随机化分析估算,降低Lp(a) 65.7 mg/dL(95%CI 46.3-88.3)可达到与降低LDL-C 38.67 mg/dL同等的冠心病结局潜在效果。
  • 该估计由观察到的SNP对Lp(a)浓度的效应决定,受Lp(a)检测标准化影响,既往对药物所需Lp(a)降低潜力的计算可能被高估。

研究设计与样本

  • 遗传流行病学研究,采用孟德尔随机化分析估算降低Lp(a)对冠心病结局所需的效应量。
  • Lp(a)效应估计来自2017年发表的GWAS和荟萃分析,包含5项以人群为基础的欧洲血统研究,所有Lp(a)测量均在1个实验室完成。
  • 使用27个单核苷酸多态性对Lp(a)浓度的遗传估计,其与冠心病风险的比值比来自CHD Exome+联盟的子样本。
  • 研究纳入Lp(a)-GWAS-Consortium的13 781名个体,以及CHD Exome+联盟子样本的20 793例冠心病病例和27 540名对照。
  • 4项研究年龄分布相似(均值51至59岁),1个队列较年轻(平均年龄32岁);女性频率相似,为51%至55%。

主要发现

  • 估算所需Lp(a)降低效应量为65.7 mg/dL(95%CI 46.3-88.3),以达到降低LDL-C 38.67 mg/dL所能达到的同等临床结局潜在效果。

临床怎么用

  • 在评估新型降Lp(a)药物时,可以降低Lp(a) 65.7 mg/dL作为达到与降低LDL-C 38.67 mg/dL同等冠心病结局效果的参考效应量。
  • 解读Lp(a)降低效应量估计时需考虑Lp(a)检测标准化对SNP效应估计的影响,避免高估药物所需降低潜力。

局限性

  • 所需Lp(a)降低效应量的估计由观察到的SNP对Lp(a)浓度的效应决定,受所用Lp(a)检测标准化影响。
  • 基于此,既往对药物所需Lp(a)降低潜力以达临床有效的计算可能被高估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Genetic and epidemiologic data suggest that lipoprotein(a) (Lp[a]) is one of the strongest genetically determined risk factors for coronary heart disease (CHD). Specific therapies to lower Lp(a) are on the horizon, but the required reduction of Lp(a) to translate into clinically relevant lowering of CHD outcomes is a matter of debate. OBJECTIVE: To estimate the required Lp(a)-lowering effect size that may be associated with a reduction of CHD outcomes compared with the effect size of low-density lipoprotein cholesterol (LDL-C)-lowering therapies. DESIGN, SETTING, AND PARTICIPANTS: Genetic epidemiologic study using a mendelian randomization analysis to estimate the required Lp(a)-lowering effect size for a clinically meaningful effect on outcomes. We used the effect estimates for Lp(a) from a genome-wide association study (GWAS) and meta-analysis on Lp(a) published in 2017 of 5 different primarily population-based studies of European ancestry. All Lp(a) measurements were performed in 1 laboratory. Genetic estimates for 27 single-nucleotide polymorphisms on Lp(a) concentrations were used. Odds ratios for these 27 single-nucleotide polymorphisms associated with CHD risk were retrieved from a subsample of the CHD Exome+ consortium. EXPOSURES: Genetic LPA score, plasma Lp(a) concentrations, and observations of statin therapies on CHD outcomes. MAIN OUTCOMES AND MEASURES: Coronary heart disease. RESULTS: The study included 13 781 individuals from the Lp(a)-GWAS-Consortium from 5 primarily population-based studies and 20 793 CHD cases and 27 540 controls from a subsample of the CHD Exome+ consortium. Four of the studies were similar in age distribution (means between 51 and 59 years), and 1 cohort was younger; mean age, 32 years. The frequency of women was similar between 51% and 55%. We estimated that the required reduction in Lp(a) effect size would be 65.7 mg/dL (95% CI, 46.3-88.3) to reach the same potential effect on clinical outcomes that can be reached by lowering LDL-C by 38.67 mg/dL (to convert to millimoles per liter, multiply by 0.0259). CONCLUSIONS AND RELEVANCE: This mendelian randomization analysis estimated a required Lp(a)-lowering effect size of 65.7 mg/dL to reach the same effect as a 38.67-mg/dL lowering of LDL-C. However, this estimate is determined by the observed effect estimates of single-nucleotide polymorphisms on Lp(a) concentrations and is therefore influenced by the standardization of the Lp(a) assay used. As a consequence, calculations of the required Lp(a)-lowering potential of a drug to be clinically effective might have been overestimated in the past.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Lamina C, Kronenberg F. Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis. JAMA Cardiol. 2019. PMID: 31017618. doi:10.1001/jamacardio.2019.1041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。